Why HyQvia?
Once-a-month* infusions. Reliable infection protection.

*Every 3 or 4 weeks.
HYQVIA is a liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in adults.
*Every 3 or 4 weeks.
*Every 3 or 4 weeks.
In the clinical trial, HyQvia provided reliable infection protection and the consistent Ig levels you expect from a subQ treatment.
HyQvia was studied in a clinical trial of 83 adults with PI with the main goal of measuring how many acute serious bacterial infections (ASBIs) they experienced over the course of 1 year. Keep scrolling to see efficacy results from the clinical trial.
ASBIs are short-term but serious infections caused by bacteria that require immediate medical care. The FDA standard for efficacy—that is, if an immunoglobulin works—is less than 1 ASBI per year. In the clinical trial, people taking HyQvia experienced significantly less than that.
ASBIs included 2 episodes of pneumonia.§
*Every 3 or 4 weeks.
‡The FDA standard for efficacy—that is, if an immunoglobulin works—is less than 1 ASBI per year. In the clinical trial, people taking HyQvia experienced significantly less than that (P< 0.0001).
§Both episodes of pneumonia were treated as outpatients with oral antibiotics. An additional episode of pneumonia requiring hospitalization occurred during the ramp-up.
In the clinical trial, patients taking HyQvia experienced an average of:
Systemic side effects affect the entire body and may occur within 72 hours, excluding infections. Local side effects occur at the infusion site.
The most common side effects observed in the clinical trial were: local side effects (pain, swelling, itching, and redness) and systemic side effects (headache, antibody formation against rHuPH20,† fatigue, nausea, fever, and vomiting).
*Every 3 or 4 weeks.
†Recombinant Human Hyaluronidase.
Rate = total number of systemic side effects divided by total number of infusions.
IVIg was administered for a median of 91 days and HYQVIA for a median of 42 days during the dose ramp-up period and 366 days during the efficacy period.
These systemic side effects occurred within 72 hours of infusion and/or were considered to be caused by the infusion.
*Excluding infections.
Local side effects like pain, swelling, itching, and redness occur at the infusion site and generally go away in a few hours. Local reactions are less likely after the first few infusions.
Mild side effect causes temporary discomfort that goes away on its own, or with little medical intervention.
Moderate side effect causes a slight decline in function that goes away on its own, or with little medical intervention, and has no further consequences.
Severe side effect results in impairment of function and can lead to temporary inability to resume normal lifestyle as it requires prolonged medical intervention and/or results in further consequences.
3 local severe reactions occurred during the clinical study: local infusion site pain, infusion site swelling, and infusion site swelling that extended from the abdominal infusion site to the genitalia.
More time between infusions.
Focusing on planning her next trip.
Mary is a thriving retiree and outdoor enthusiast who has been a HyQvia patient for years. Although she works closely with her doctor, she says PI treatment is just one part of her life. It doesn't define who she is.